• Dattatray J. Patil
• Dr. Kiran A. Wadkar
• Dr. Manish S. Kondawar

The basic aim of this study deals with formulation and evaluation of Ribavirin DPI for pulmonary delivery by Lyophillization. Ribavirin is an antiviral medication used to treat RSV infection, hepatitis C and viral hemorrhagic fever. Ribavirin formulation available in the form of tablet, capsule and inhalation solution. For inhalation solutions mechanical instruments are required, and they can be overcome by use liposomes, dry powder inhalation meter dose inhalation etc. Total 6 batches were prepared and subjected for evaluation of flow properties. All the parameters were within limits as per Indian pharmacopeia which shows good flow properties, Particle size, Zeta potential, DSC, XRD. Drug and excipient compatibility was carried out by FTIR spectroscopy. In-vitro dissolution study was performed which shows batch B as a optimized batch because of low concentration of polymers in formulation. The developed formulation was found to be stable during the stability studies of 3 months.

Ribavirin, DPI, Particle Size, In vitro Aerosolization, In vitro dissolution.

"“FORMULATION AND EVALUATION OF RIBAVIRIN DRY POWDER INHALATION FOR PULMONARY DELIVERY BY LYOPHILLIZATION”", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 6, page no.234-270, June 2019, Available :http://www.jetir.org/papers/JETIR1907926.pdf

"“FORMULATION AND EVALUATION OF RIBAVIRIN DRY POWDER INHALATION FOR PULMONARY DELIVERY BY LYOPHILLIZATION”", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 6, page no. pp234-270, June 2019, Available at : http://www.jetir.org/papers/JETIR1907926.pdf